{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:34:14Z","timestamp":1769276054848,"version":"3.49.0"},"reference-count":61,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Psoriasis and psoriatic arthritis (PsA) development is sustained by tumor necrosis factor (TNF)\u03b1, interleukin (IL)17, and IL23; hence, biologics targeting those cytokines represent useful therapeutic weapons for both conditions. Nevertheless, biologics strongly reduce PsA risk; several studies reported the possibility of new-onset PsA during biologic therapy for psoriasis. The aim of this 1-year prospective study is to evaluate the prevalence of paradoxical PsA in psoriasis patients under biologic therapy and review the existing literature. For each patient, age, sex, psoriasis duration, psoriasis severity, comorbidities, and previous and current psoriasis treatments were collected, and each subject was screened for PsA using the Early ARthritis for Psoriatic patient (EARP) questionnaire every 3 months for 1 year. New-onset PsA was diagnosed in 10 (8.5%) out of 118 patients (three male, 30.0%; mean age 44.5 years) involving every different biologic class (anti-TNF, anti-IL12\/23, anti-IL17, and anti-IL23). No significant risk factor for new-onset PsA was identified; no significant difference was found comparing patients who developed PsA and subjects who did not develop PsA regarding psoriasis severity, past\/current therapies, and comorbidities. Clinicians must keep in mind the possibility of PsA onset also in patients undergoing biologics so that PsA screening should be strongly recommended at each follow-up.<\/jats:p>","DOI":"10.3390\/biomedicines9101482","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T23:13:32Z","timestamp":1634512412000},"page":"1482","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-2046","authenticated-orcid":false,"given":"Matteo","family":"Megna","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia Sofia","family":"Ocampo-Garza","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"},{"name":"Dermatology Department, Hospital Universitario \u201cDr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey 64460, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Fontanella","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Gallo","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3864-216X","authenticated-orcid":false,"given":"Sara","family":"Cacciapuoti","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-7391","authenticated-orcid":false,"given":"Angelo","family":"Ruggiero","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s10067-016-3295-9","article-title":"Psoriatic arthritis and psoriasis: Differential diagnosis","volume":"35","author":"Napolitano","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_4","first-page":"1945","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: What is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e15030","DOI":"10.1111\/dth.15030","article-title":"Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?","volume":"34","author":"Megna","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum."},{"key":"ref_10","first-page":"1022","article-title":"Clinical and radiological changes during psoriatic arthritis disease progression","volume":"30","author":"Khan","year":"2003","journal-title":"J. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","article-title":"Patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: Elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative","volume":"73","author":"Gossec","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","first-page":"S700","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4081\/reumatismo.2012.66","article-title":"Epidemiology of psoriatic arthritis","volume":"64","author":"Catanoso","year":"2012","journal-title":"Reumatismo"},{"key":"ref_14","first-page":"ii7","article-title":"Psoriatic arthritis: Epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/ajd.13484","article-title":"Is there any association between psoriasis, psoriatic arthritis and thyroid autoimmunity?","volume":"62","author":"Vastarella","year":"2021","journal-title":"Australas J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40257-015-0169-x","article-title":"US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey","volume":"17","author":"Lebwohl","year":"2015","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","article-title":"Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and me-ta-analysis","volume":"73","author":"Villani","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/09546634.2019.1605142","article-title":"Psoriatic arthritis for dermatologists","volume":"31","author":"Gottlieb","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_21","first-page":"172","article-title":"Psoriatic arthritis classification criteria: Moll and Wright, ESSG and CASPAR\u2014A comparative study","volume":"38","author":"Stojanovic","year":"2013","journal-title":"Acta Reum. Port."},{"key":"ref_22","first-page":"137","article-title":"Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: A combined dermatology and rheumatology clinical study","volume":"35","author":"Napolitano","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_23","first-page":"29","article-title":"The Skin May Clear but the Arthritis Won\u2019t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy","volume":"10","year":"2020","journal-title":"Psoriasis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/1346-8138.13987","article-title":"New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study","volume":"44","author":"Asahina","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1590\/abd1806-4841.20132487","article-title":"Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab\u2014A paradoxical effect? A case report","volume":"88","author":"Santos","year":"2013","journal-title":"An. Bras. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000479475","article-title":"Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others","volume":"53","author":"Puig","year":"2018","journal-title":"Curr. Probl. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2193-1801-3-759","article-title":"Simple clinical indicators for early psoriatic arthritis detection","volume":"3","author":"Caso","year":"2014","journal-title":"SpringerPlus"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s10067-018-4238-4","article-title":"Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: Two-year clinical experience of a dermo-rheumatologic clinic","volume":"37","author":"Luchetti","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_29","first-page":"1","article-title":"Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs","volume":"36","author":"Keskin","year":"2021","journal-title":"Arch. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Narcisi, A., Valenti, M., de Simone, C., Esposito, M., Richetta, A., Teoli, M., Argento, G., and Costanzo, A. (2021). Effects of TNF-\u03b1 inhibition on pre-clinical enthesitis: Observational study on 49 psoriatic patients. J. Dermatol. Treat., 1\u20134.","DOI":"10.1080\/09546634.2021.1899112"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/art.40778","article-title":"Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated with Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study","volume":"71","author":"Savage","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/14712598.2018.1479738","article-title":"Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future","volume":"18","author":"Raimondo","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3899\/jrheum.140876","article-title":"Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review","volume":"41","author":"Felquer","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2012-201706","article-title":"High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires","volume":"72","author":"Haroon","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/bjd.13587","article-title":"Arthritis possibly induced and exacerbated by a tumour necrosis factor antagonist in a patient with psoriasis vulgaris","volume":"172","author":"Takahashi","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2133.2012.11206.x","article-title":"Inflammatory arthritis following ustekinumab treatment for psoriasis: A report of two cases","volume":"168","year":"2013","journal-title":"Br J Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/bjd.13645","article-title":"Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: A case series of seven patients","volume":"173","author":"Jones","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamadermatol.2013.5728","article-title":"Ustekinumab Associated with Flares of Psoriatic Arthritis","volume":"149","author":"Stamell","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/kev263","article-title":"Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab","volume":"54","year":"2015","journal-title":"Rheumatology"},{"key":"ref_40","first-page":"370","article-title":"\u201cParadoxical joint inflammation\u201d possibly induced by a tumor necrosis factor antagonist in three patients with psoriasis","volume":"155","author":"Ferrucci","year":"2020","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ad.2017.12.011","article-title":"Paradoxical Arthritis Due to Ixekizumab in a Patient with Plaque Psoriasis","volume":"110","author":"Vidal","year":"2019","journal-title":"Actas Dermosifiliogr."},{"key":"ref_42","first-page":"156","article-title":"Adverse reactions during biological therapy for psoriasis: Results of a survey of the Spanish Psoriasis Group","volume":"101","year":"2010","journal-title":"Actas Dermosifiliogr."},{"key":"ref_43","unstructured":"Gottlieb, A.B., and Merola, J.F. (2021). A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis. J. Dermatol. Treat., 1\u20139."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The Incidence and Risk Factors for Psoriatic Arthritis in Patients with Psoriasis: A Prospective Cohort Study","volume":"68","author":"Eder","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2340\/00015555-2808","article-title":"Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis","volume":"98","author":"Furue","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2018.08.025","article-title":"Differential efficacy of biologic treatments targeting the TNF-\u03b1\/IL-23\/IL-17 axis in psoriasis and psoriatic arthritis","volume":"111","author":"Furue","year":"2018","journal-title":"Cytokine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American college of rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Gisondi, P., Bellinato, F., Targher, G., Idolazzi, L., and Girolomoni, G. (2021). Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann. Rheum. Dis.","DOI":"10.1136\/annrheumdis-2021-219961"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Acosta Felquer, M.L., and LoGiudice, L. (2021). Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann. Rheumatol. Dis., 220865.","DOI":"10.1136\/annrheumdis-2021-220865"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1365-2133.2009.09329.x","article-title":"Cytokine imbalance with increased production of interferon-\u03b1 in psoriasiform eruptions associated with antitumour necrosis factor-\u03b1 treatments","volume":"161","author":"Seneschal","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/1744666X.2019.1543591","article-title":"The relationship between smoking, psoriasis and psoriatic arthritis","volume":"15","author":"Pezzolo","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jbspin.2014.01.004","article-title":"Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNF\u03b1 blocker","volume":"81","author":"Villani","year":"2014","journal-title":"Jt. Bone Spine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.revmed.2014.09.001","article-title":"Psoriatic arthritis during rituximab treatment of granulomatosis with polyangiitis: A new paradoxical side effect?","volume":"36","author":"Aussy","year":"2015","journal-title":"Rev. Med. Interne."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e000667","DOI":"10.1136\/rmdopen-2018-000667","article-title":"Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: Histological and immunological features of a complex synovitis","volume":"4","author":"Alivernini","year":"2018","journal-title":"RMD Open"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1093\/ibd\/izz019","article-title":"Paradoxical Arthritis in Inflammatory Bowel Diasease Patients on Ustekinumab Treatment","volume":"25","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/rheumatology\/keaa692","article-title":"Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: Results from a national register-based cohort study","volume":"60","author":"Bengtsson","year":"2020","journal-title":"Rheumatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"ref_61","first-page":"797","article-title":"Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: Findings in the Biobadaderm cohort","volume":"176","author":"Carrascosa","year":"2016","journal-title":"Br. J. Dermatol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1482\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:15:52Z","timestamp":1760166952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["biomedicines9101482"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9101482","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]}}}